Modality
Fusion Protein
MOA
PD-1i
Target
CD47
Pathway
PI3K/AKT
MesoAngelman
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
~Feb 2017
→ ~May 2018
Phase 2
Aug 2018
→ Apr 2029
Phase 2Current
NCT07532913
2,600 pts·Meso
2018-08→TBD·Active
NCT04216996
953 pts·Meso
2021-07→2029-04·Active
3,553 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-182mo agoAdCom· Meso
2029-04-013.0y awayPh3 Readout· Meso
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2/3
Active
P2/3
Active
Catalysts
AdCom
2026-01-18 · 2mo ago
Meso
Ph3 Readout
2029-04-01 · 3.0y away
Meso
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07532913 | Phase 2/3 | Meso | Active | 2600 | VA |
| NCT04216996 | Phase 2/3 | Meso | Active | 953 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 |